Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.

Pfizer Inc. (PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization ...

Canada will not be providing Novavax for the 2024/25 season, leaving those who would have preferred an alternative to the ...

LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the ...